This article has Open Peer Review reports available.
Salmonella aortitis treated with endovascular aortic repair: a case report
© Strahm et al.; licensee BioMed Central Ltd. 2012
Received: 7 December 2011
Accepted: 28 May 2012
Published: 15 August 2012
Salmonella is a typical cause of aortitis, which is associated with high morbidity and mortality. In infrarenal disease, besides open surgery, endovascular aortic repair as an alternative treatment has been reported. To the best of our knowledge, we report the first successful endovascular aortic repair documented by necropsy to date.
A 67-year-old Caucasian man presented with low back pain, fever and positive blood cultures for Salmonella Enteritidis. A computed tomography scan showed an enlargement and intramural hematoma of the infrarenal aortic wall; a Salmonella aortitis was suspected and antimicrobial therapy initiated. Because of substantial comorbidities, endovascular aortic repair was favored over open surgery; postoperatively the antibiotic treatment was continued for 12 months. Post-mortem there were neither macroscopic nor microscopic signs of aortitis or graft infection.
We could demonstrate by necropsy that endovascular aortic repair of infrarenal aortitis with prolonged pre- and postinterventional antibiotic therapy for 12 months was a minimally invasive alternative and should be considered in selected clinically stable patients with substantial co-morbidities.
KeywordsSalmonella Enteritidis Aortitis Mycotic aneurysm EVAR Endovascular aortic repair
Infectious aortitis is a rare but life-threatening disorder . Usually a combined strategy of antibiotic treatment and surgical debridement is required, although no controlled clinical trials have explored its optimal management. Despite aggressive therapeutic approaches mortality remains high [2–7]. An alternative is combined medical and endovascular management. We report the case of a patient with aortitis due to Salmonella Enteritidis that was successfully treated with endovascular aortic repair (EVAR) and antibiotic therapy as confirmed by autopsy.
Infectious aortitis is an inflammatory process within the arterial wall caused by microorganisms. As a complication, microbial arteritis with aneurysm can develop. Possible mechanisms are septic emboli to the vasa vasorum, continuous infection from a focus extending to the arterial wall, direct bacterial inoculation and bacterial seeding in an existing intimal injury or an atherosclerotic plaque . Typical risk factors are male gender, age over 50 years, diabetes, and pathological alterations of the aortic wall (most commonly atherosclerosis) . The most frequently isolated pathogens are Salmonella and staphylococcal species [8, 9].
Diagnosis is based on the clinical picture, radiographic imaging, and culture results. Because of the nonspecific presentation with back pain or abdominal discomfort and fever, the diagnosis of infectious aortitis requires a high index of suspicion . Nevertheless, an early diagnosis is crucial, because microbial arteritis with aneurysm is associated with a high rate of rupture and subsequent mortality if left untreated. Once the diagnosis is made, a rapid empirical intravenous antibiotic therapy is important while awaiting microbiological data from blood cultures [1, 2].
A 67-year-old Caucasian man presented to the emergency department with back and abdominal pain, fever and malaise. He reported that his wife and granddaughter had previously suffered from mild gastroenteritis. He had a history of colorectal cancer with a solitary metastasis (7 × 7.5cm) of the abdominal wall, and previously underwent aortocoronary bypass surgery and mitral valve reconstruction. On examination, he was febrile (38.5°C axillary) with otherwise normal vital signs. The abdomen was distended with discomfort on deep palpation with a palpable mass in the abdominal wall. The lower spine was tender on percussion.
Laboratory values at hospital admission (19 days before EVAR), ten days before EVAR and shortly before the EVAR with follow-up at discharge and after three, six, 12 and 15 months
The mortality of infectious aortitis and mycotic aneurysm is high and depends on rapid diagnostic workup, location of the diseased artery and type of therapy as well as the underlying condition of the patient . In the largest case series with combined surgical and antibiotic treatment, an early mortality of 11% to 36% is documented [6, 7]. Medical management without surgery is fatal in greater than 90% of cases .
Wang et al.  reported that 35% of adults above 65 years of age with positive blood cultures for non-typhoid Salmonella had aortitis. Common risk factors for invasive non-typhoid salmonellosis are immunodeficiency and solid-organ cancer . Since most patients have severe comorbidity an open surgical procedure carries a high perioperative risk .
A less invasive approach, namely, combined medical and endovascular management has been introduced by Semba et al. . So far, only case reports and small series of successful EVAR of infectious aortitis have been reported and reviewed; hence, it is still considered an experimental procedure [3, 6]. Regardless, EVAR has changed the management of primary mycotic aneurysm over the last decades . At present, it is probably best documented for Salmonella infection [15, 16].
Based on available data, the early mortality rate associated with stent-grafts appears to be lower than the one associated with conventional surgery. In a recent small multi-institutional case series, EVAR performed in selected patients showed a very good outcome with no in-hospital mortality and only one unrelated late death . However, late aneurysm-related events including mortality and complications seem to be more common than with surgery , because there is obviously no possibility to debride the infectious tissue and the infected aortic wall . As the majority of late events resulted from inadequate control of infection, an appropriate preoperative antibiotic treatment preferably with clearance of the bacteremia as well as long-term treatment after EVAR is mandatory [3, 6]. Various factors including anatomic location of the infection (infrarenal, paravisceral, or thoracic aorta), the nature (fistula versus mycotic aneurysm), the microbial features, the general condition and the morbidity of the patient should be considered before establishing endovascular treatment as a viable option. It is difficult to define which cases should be treated endoluminally and it seems that the endovascular technique should be used only for specific indications, such as absence of gross purulence, gross infection, aorto-digestive fistula and uncontrolled sepsis and in the presence of a high operative risk [16, 18].
Our patient had severe comorbidity and there were neither signs of gross purulence nor fistula. In addition, he responded rapidly to antibiotic therapy. After five days the blood cultures turned negative and several follow-up blood cultures remained negative.
Therefore, we favored an EVAR without delay in this setting.
The optimal antibiotic agent and duration of treatment after EVAR remains controversial and some authors recommend lifelong resumption [15, 16]. Prolonged antibiotic therapy is generally considered necessary . In our case, after successful EVAR, an intravenous antibiotic therapy was continued for 10 more days. Since at that time our patient was in a good general condition, we switched to an oral monotherapy with ciprofloxacin, which was resumed for a period of 12 months. The duration of antibiotic therapy was chosen empirically because simultaneously there was maintenance chemotherapy for his colon cancer, which was considered as immunosuppression. Given normal C-reactive protein, leukocyte counts, clinical status and negative computed tomography (CT) the antibiotic therapy was stopped.
In device-associated infections due to gram-negative rods fluoroquinolones should be favored, because quinolones are active against adherent and nongrowing Escherichia coli . In addition, in an animal model of implant-associated infection, ciprofloxacin was better than cotrimoxazole against S. Dublin . Another reason in favor of quinolones is the intracellular bactericidal activity against non-typhoid Salmonella in vitro as shown by Chiu et al. .
Careful follow-up is of great importance to detect persistent infection, endoleaks and migration of the graft [1, 6]. Our patient underwent CT scans three, six, 12 and 15 months after EVAR and was stable at follow-up without signs of therapy failure (Figure 2).
Four months after suspension of antibiotic therapy the patient died in the course of an ileus. As post-mortem examination found no evidence of active inflammation of the aorta or signs of stent failure, one could assume the patient to be cured of the infection.
To conclude, it was shown that EVAR with prolonged antibiotic treatment with an active antibiotic against adherent bacteria for 12 months can be considered as an efficacious alternative strategy in appropriate patients with infectious aortitis due to S. Enteritidis.
Written informed consent was obtained from the patient prior to his death for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Thanks to Dr Suter for critically reviewing the manuscript and Dr Lienemann for reconstruction of computer tomographic studies.
- Foote EA, Postier RG, Greenfield RA, Bronze MS: Infectious aortitis. Curr Treat Options Cardiovasc Med. 2005, 7: 89-97. 10.1007/s11936-005-0010-6.View ArticlePubMedGoogle Scholar
- Hsu RB, Chen RJ, Wang SS, Chu SH: Infected aortic aneurysms: clinical outcome and risk factor analysis. J Vasc Surg. 2004, 40: 30-35. 10.1016/j.jvs.2004.03.020.View ArticlePubMedGoogle Scholar
- Kan CD, Lee HL, Yang YJ: Outcome after endovascular stent graft treatment for mycotic aortic aneurysm: a systematic review. J Vasc Surg. 2007, 46: 906-912. 10.1016/j.jvs.2007.07.025.View ArticlePubMedGoogle Scholar
- Muller BT, Wegener OR, Grabitz K, Pillny M, Thomas L, Sandmann W: Mycotic aneurysms of the thoracic and abdominal aorta and iliac arteries: experience with anatomic and extra-anatomic repair in 33 cases. J Vasc Surg. 2001, 33: 106-113.View ArticlePubMedGoogle Scholar
- Oderich GS, Panneton JM, Bower TC, Cherry KJ, Rowland CM, Noel AA, Hallett JW, Gloviczki P: Infected aortic aneurysms: aggressive presentation, complicated early outcome, but durable results. J Vasc Surg. 2001, 34: 900-908. 10.1067/mva.2001.118084.View ArticlePubMedGoogle Scholar
- Razavi MK, Razavi MD: Stent-graft treatment of mycotic aneurysms: a review of the current literature. J Vasc Interv Radiol. 2008, 19: S51-56.View ArticlePubMedGoogle Scholar
- Yu SY, Hsieh HC, Ko PJ, Huang YK, Chu JJ, Lee CH: Surgical outcome for mycotic aortic and iliac anuerysm. World J Surg. 2011, 35: 1671-1678. 10.1007/s00268-011-1104-9.View ArticlePubMedGoogle Scholar
- Cina CS, Arena GO, Fiture AO, Clase CM, Doobay B: Ruptured mycotic thoracoabdominal aortic aneurysms: a report of three cases and a systematic review. J Vasc Surg. 2001, 33: 861-867. 10.1067/mva.2001.111977.View ArticlePubMedGoogle Scholar
- Brown SL, Busuttil RW, Baker JD, Machleder HI, Moore WS, Barker WF: Bacteriologic and surgical determinants of survival in patients with mycotic aneurysms. J Vasc Surg. 1984, 1: 541-547.View ArticlePubMedGoogle Scholar
- Soravia-Dunand VA, Loo VG, Salit IE: Aortitis due to Salmonella: report of 10 cases and comprehensive review of the literature. Clin Infect Dis. 1999, 29: 862-868. 10.1086/520450.View ArticlePubMedGoogle Scholar
- Wang JH, Liu YC, Yen MY, Wang JH, Chen YS, Wann SR, Cheng DL: Mycotic aneurysm due to non-typhi salmonella: report of 16 cases. Clin Infect Dis. 1996, 23: 743-747. 10.1093/clinids/23.4.743.View ArticlePubMedGoogle Scholar
- Hsu RB, Tsay YG, Chen RJ, Chu SH: Risk factors for primary bacteremia and endovascular infection in patients without acquired immunodeficiency syndrome who have nontyphoid salmonellosis. Clin Infect Dis. 2003, 36: 829-834. 10.1086/367932.View ArticlePubMedGoogle Scholar
- Semba CP, Sakai T, Slonim SM, Razavi MK, Kee ST, Jorgensen MJ, Hagberg RC, Lee GK, Mitchell RS, Miller DC, Dake MD: Mycotic aneurysms of the thoracic aorta: repair with use of endovascular stent-grafts. J Vasc Interv Radiol. 1998, 9: 33-40.View ArticlePubMedGoogle Scholar
- Vallejo N, Picardo NE, Bourke P, Bicknell C, Cheshire NJ, Jenkins MP, Wolfe J, Gibbs RG: The changing management of primary mycotic aortic aneurysms. J Vasc Surg. 2011, 54: 334-340. 10.1016/j.jvs.2010.12.066.View ArticlePubMedGoogle Scholar
- Kan CD, Yen HT, Kan CB, Yang YJ: The feasibility of endovascular aortic repair strategy in treating infected aortic aneurysms. J Vasc Surg. 2012, 55: 55-60. 10.1016/j.jvs.2011.07.077.View ArticlePubMedGoogle Scholar
- Kritpracha B, Premprabha D, Sungsiri J, Tantarattanapong W, Rookkapan S, Juntarapatin P: Endovascular therapy for infected aortic aneurysms. J Vasc Surg. 2011, 54: 1259-1265. 10.1016/j.jvs.2011.03.301. discussion 1265View ArticlePubMedGoogle Scholar
- Forbes TL, Harding GE: Endovascular repair of Salmonella-infected abdominal aortic aneurysms: a word of caution. J Vasc Surg. 2006, 44: 198-200. 10.1016/j.jvs.2006.03.002.View ArticlePubMedGoogle Scholar
- Gonzalez-Fajardo JA, Gutierrez V, Martin-Pedrosa M, Del Rio L, Carrera S, Vaquero C: Endovascular repair in the presence of aortic infection. Ann Vasc Surg. 2005, 19: 94-98. 10.1007/s10016-004-0144-0.View ArticlePubMedGoogle Scholar
- Widmer AF, Wiestner A, Frei R, Zimmerli W: Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections. Antimicrob Agents Chemother. 1991, 35: 741-746. 10.1128/AAC.35.4.741.View ArticlePubMedPubMed CentralGoogle Scholar
- Widmer AF, Colombo VE, Gachter A, Thiel G, Zimmerli W: Salmonella infection in total hip replacement: tests to predict the outcome of antimicrobial therapy. Scand J Infect Dis. 1990, 22: 611-618. 10.3109/00365549009027105.View ArticlePubMedGoogle Scholar
- Chiu CH, Lin TY, Ou JT: In vitro evaluation of intracellular activity of antibiotics against non-typhoid Salmonella. Int J Antimicrob Agents. 1999, 12: 47-52. 10.1016/S0924-8579(99)00038-2.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.